Kisho

Teva Pharmaceuticals USA, Inc. — Rare Disease Pipeline | Kisho | Kisho

Teva Pharmaceuticals USA, Inc.

Other

A pharmaceutical company engaged in developing treatments for rare diseases, with 19 FDA-approved drugs and 3 orphan drug designations, focusing on conditions like hypoglycemia and various forms of hypertension.

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
allergic disease	Copaxone	Orphan Designation	-
anosmia for isobutyric acid	Copaxone	Orphan Designation	-
autoimmune disorder of the nervous system	Copaxone	Orphan Designation	-
benign essential hypertension	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	-	FDA Approved
benign partial epilepsy of infancy with complex partial seizures	TIAGABINE HYDROCHLORIDE	-	FDA Approved
essential hypertension	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	-	FDA Approved
familial hypocalciuric hypercalcemia 3	Secalciferol	Orphan Designation	-
familial isolated hyperparathyroidism	Secalciferol	Orphan Designation	-
hyperparathyroidism 2 with jaw tumors	Secalciferol	Orphan Designation	-
hypoglycemia	PROGLYCEM	-	FDA Approved
malignant essential hypertension	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	-	FDA Approved
malignant migrating partial seizures of infancy	TIAGABINE HYDROCHLORIDE	-	FDA Approved
mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome	Glatiramer acetate for injection	Orphan Designation	-
multiple sclerosis	Copaxone	Orphan Designation	-
primary progressive multiple sclerosis	Glatiramer acetate for injection	Orphan Designation	-
renal hypertension	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	-	FDA Approved
secondary hypertension	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	-	FDA Approved
semantic dementia	Glatiramer acetate for injection	Orphan Designation	-

← Back to Companies